AUTHOR=Zhang Lin , Mai Wuqian , Jiang Wenyang , Geng Qing 

TITLE=Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer

JOURNAL=Frontiers in Surgery

VOLUME=Volume 7 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2020.601805

DOI=10.3389/fsurg.2020.601805

ISSN=2296-875X

ABSTRACT=The emergence of PD-1 antibodies has radically changed the therapeutic profiles of lung cancer, which has the highest incidence and mortality among all cancers in the world. Pembrolizumab, an anti-PD-1 antibody, has been proved to have strong anti-tumor activity in a variety of clinical studies. Here, we described a patient with stage IIB squamous lung cancer who has benefited from a preoperative pembrolizumab plus chemotherapy regimen. The addition of pembrolizumab to neoadjuvant chemotherapy before surgery has lead to pathologic complete response and the avoidance of left pneumonectomy. This case highlights the effect of neoadjuvant pembrolizumab plus chemotherapy on non small cell lung cancer patient and has provided a promising choice in future clinical practice.